These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

340 related items for PubMed ID: 26538503

  • 1. Population pharmacokinetics of linezolid in critically ill patients on renal replacement therapy: comparison of equal doses in continuous venovenous haemofiltration and continuous venovenous haemodiafiltration.
    Roger C, Muller L, Wallis SC, Louart B, Saissi G, Lipman J, Lefrant JY, Roberts JA.
    J Antimicrob Chemother; 2016 Feb; 71(2):464-70. PubMed ID: 26538503
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration.
    Roberts JA, Udy AA, Bulitta JB, Stuart J, Jarrett P, Starr T, Lassig-Smith M, Roberts NA, Dunlop R, Hayashi Y, Wallis SC, Lipman J.
    J Antimicrob Chemother; 2014 Sep; 69(9):2508-16. PubMed ID: 24879665
    [Abstract] [Full Text] [Related]

  • 5. Caspofungin Population Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-Venous Haemofiltration or Haemodiafiltration.
    Roger C, Wallis SC, Muller L, Saissi G, Lipman J, Brüggemann RJ, Lefrant JY, Roberts JA.
    Clin Pharmacokinet; 2017 Sep; 56(9):1057-1068. PubMed ID: 28035589
    [Abstract] [Full Text] [Related]

  • 6. Piperacillin population pharmacokinetics in critically ill patients with multiple organ dysfunction syndrome receiving continuous venovenous haemodiafiltration: effect of type of dialysis membrane on dosing requirements.
    Ulldemolins M, Martín-Loeches I, Llauradó-Serra M, Fernández J, Vaquer S, Rodríguez A, Pontes C, Calvo G, Torres A, Soy D.
    J Antimicrob Chemother; 2016 Jun; 71(6):1651-9. PubMed ID: 26869692
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Population pharmacokinetics and dose simulation of vancomycin in critically ill patients during high-volume haemofiltration.
    Escobar L, Andresen M, Downey P, Gai MN, Regueira T, Bórquez T, Lipman J, Roberts JA.
    Int J Antimicrob Agents; 2014 Aug; 44(2):163-7. PubMed ID: 24837847
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics and Pharmacodynamics of Linezolid in Patients With Sepsis Receiving Continuous Venovenous Hemofiltration and Extended Daily Hemofiltration.
    Zheng J, Sun Z, Sun L, Zhang X, Hou G, Han Q, Li X, Liu G, Gao Y, Ye M, Wang H, Yu K.
    J Infect Dis; 2020 Mar 16; 221(Suppl 2):S279-S287. PubMed ID: 32176792
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients.
    Fish DN, Teitelbaum I, Abraham E.
    Antimicrob Agents Chemother; 2005 Jun 16; 49(6):2421-8. PubMed ID: 15917542
    [Abstract] [Full Text] [Related]

  • 14. A Population Pharmacokinetic Model-Guided Evaluation of Ceftolozane-Tazobactam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration.
    Sime FB, Lassig-Smith M, Starr T, Stuart J, Pandey S, Parker SL, Wallis SC, Lipman J, Roberts JA.
    Antimicrob Agents Chemother; 2019 Dec 20; 64(1):. PubMed ID: 31658965
    [Abstract] [Full Text] [Related]

  • 15. An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration.
    D'Arcy DM, Casey E, Gowing CM, Donnelly MB, Corrigan OI.
    BMC Pharmacol Toxicol; 2012 Nov 08; 13():14. PubMed ID: 23136834
    [Abstract] [Full Text] [Related]

  • 16. Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration.
    DelDot ME, Lipman J, Tett SE.
    Br J Clin Pharmacol; 2004 Sep 08; 58(3):259-68. PubMed ID: 15327585
    [Abstract] [Full Text] [Related]

  • 17. Linezolid extracorporeal removal during haemodialysis with high cut-off membrane in critically ill patients.
    Villa G, Cassetta MI, Tofani L, Valente S, Chelazzi C, Falsini S, De Gaudio AR, Novelli A, Ronco C, Adembri C.
    Int J Antimicrob Agents; 2015 Oct 08; 46(4):465-8. PubMed ID: 26315198
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Population pharmacokinetic/pharmacodynamic evaluations of amikacin dosing in critically ill patients undergoing continuous venovenous hemodiafiltration.
    Li S, Zhu S, Xie F.
    J Pharm Pharmacol; 2023 Apr 07; 75(4):515-522. PubMed ID: 36847263
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.